Structure Therapeutics, Inc. (GPCR)

35.76 -0.19 (-0.53%) USD  |  NASDAQ  |  Sep 24, 10:55
More

Structure Therapeutics Cash from Operations (TTM) : -220.84M for June 30, 2026

Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for GPCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2023. Start Trial.
Date Value
June 30, 2026 -220.84M
March 31, 2026 -155.20M
December 31, 2025 -222.79M
September 30, 2025 -194.53M
June 30, 2025 -163.35M
March 31, 2025 -134.97M
Date Value
December 31, 2024 -116.69M
September 30, 2024 -102.17M
June 30, 2024 -103.02M
March 31, 2024 -93.27M
December 31, 2023 -79.42M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Eli Lilly & Co. 28.08B
Novo Nordisk A/S 20.59B
Pfizer Inc. 13.40B
Johnson & Johnson 27.61B
Merck & Co., Inc. 19.97B